High Lp(a) and life expectancy: roughly a year or two, concentrated in the top 5% of levels

The short answer. For most people with a high Lp(a), the measured effect on lifespan is small. The largest gaps sit in the top 5% of levels and come to roughly one to two years of average survival. In two Danish general-population studies, Langsted and colleagues (2019) reported median survival of 83.9 years above 93 mg/dL (199 nmol/L) and 85.1 years at or below it. Those are group averages from observational data. They do not predict how long you will live.

What Lp(a) is. Lp(a) is an LDL particle with a second protein, apolipoprotein(a), attached to it. The 2022 European Atherosclerosis Society (EAS) consensus statement says more than 90% of the variation in blood levels comes from variants at the LPA gene, that the gene is fully expressed by age 2, and that adult levels are usually reached by about age 5. A pooled analysis of 36 prospective studies found levels consistent within a person over several years. Lifestyle moves it little. The EAS table lists physical activity and fasting as having no or minimal effect, and diet changes as shifting it by roughly 10% to 15%.

What counts as high. The EAS statement uses under 30 mg/dL (75 nmol/L) to rule out extra risk and over 50 mg/dL (125 nmol/L) to rule it in, with a grey zone between. The 2024 National Lipid Association update uses the same cut points and says about 1 in 5 people have an elevated level. Healio’s summary of the 2026 ACC/AHA dyslipidemia guideline says it treats 125 nmol/L or higher as a risk enhancer (about 1.4-fold ASCVD risk) and 250 nmol/L or higher as more than a doubling. Those lines mark cardiovascular risk. The top-5% group where the lifespan gap shows up starts higher, at 199 nmol/L in Denmark.

The units do not convert cleanly. The EAS panel recommends against a standard factor for converting mg/dL to nmol/L because assays vary, and calls 2 to 2.5 a best guess. Cohorts show the problem: the top 5% starts at 93 mg/dL in the Danish data and 69.7 mg/dL in EPIC-Norfolk. Compare your result with the threshold in the unit printed on your report.

The Danish cohort. Langsted’s analysis drew on two prospective Danish studies, with Lp(a) measured in 69,764 people. Compared with people below 10 mg/dL (18 nmol/L, the bottom half), those above 93 mg/dL had a hazard ratio of 1.20 (95% CI 1.10 to 1.30) for all-cause mortality and 1.50 (1.28 to 1.76) for cardiovascular mortality. The median-survival gap of 83.9 versus 85.1 years had a log-rank P of 0.005. That is 1.2 years, in the top 5% only.

The UK cohorts and parental lifespan. Arsenault and colleagues (2020) used genetics. In 139,362 UK Biobank participants, a genetic score for higher Lp(a), scaled to a 50 mg/dL rise, was linked to lower odds of having a long-lived parent (odds ratio 0.92, 95% CI 0.89 to 0.94). They defined long-lived as a father who reached 90 or a mother who reached 93. In 18,720 people in EPIC-Norfolk, followed for a mean of 20 years, those at or above the 95th percentile (69.7 mg/dL and up) had an adjusted all-cause mortality hazard ratio of 1.22 (1.09 to 1.37) against those below the median. The authors restated that as the risk of being 1.5 years older. That is a risk-equivalent age, not a count of years lost. They called the results a "potential causal effect" and said only a long-term trial of Lp(a) lowering can show clinical benefit.

Where the gap shows up, and where it does not. The same EPIC-Norfolk table splits people by percentile. Against the bottom half, the hazard ratio for all-cause mortality was 0.94 (0.89 to 1.00) at 11.4 to under 35 mg/dL and 1.06 (0.97 to 1.16) at 35.0 to under 53.3 mg/dL, the band that straddles the guideline’s 50 mg/dL line. It reached 1.13 (1.00 to 1.27) at 53.3 to under 69.7 mg/dL. The EAS statement likewise notes that the risk of cardiovascular death and ischaemic stroke only rises at very high levels, above the 95th percentile. The Emerging Risk Factors Collaboration pooled 126,634 people from 36 prospective studies and found no association with cancer deaths (risk ratio 1.00, 0.97 to 1.04) or with other non-vascular deaths. It described the associations as exclusive to vascular outcomes.

How strong the evidence is. A 2023 dose-response meta-analysis pooled 75 prospective studies (957,253 participants). In the general population, the top third of Lp(a) against the bottom third carried a hazard ratio of 1.09 (1.01 to 1.18) for all-cause mortality and 1.33 (1.11 to 1.58) for cardiovascular mortality. The all-cause estimate varied a lot between studies (I² 75%). The EAS statement, written before that meta-analysis, marks all-cause mortality as "No" for meta-analyses of prospective studies in its evidence table, "Yes" for large prospective cohorts and Mendelian randomization, and lists a trial of Lp(a) lowering as ongoing. The all-cause link is a small, observational one.

Genetics points the same way, with exceptions. In the Danish data, a genetic proxy based on the LPA kringle-IV type 2 repeat number gave a risk ratio of 1.10 (1.04 to 1.18) for all-cause mortality per 50 mg/dL. A proxy based on a single variant, rs10455872, gave 0.97 (0.92 to 1.02), no effect. A 2022 Nature Aging study that combined six aging traits reported evidence for a detrimental effect of blood apolipoprotein(a) on a composite aging measure. I read only its abstract. Arsenault’s team notes their cohorts are of European ancestry only, while Lp(a) differs by ancestry: the EAS statement reports UK Biobank medians of 16, 19, 31 and 75 nmol/L in Chinese, White, South Asian and Black participants.

If your Lp(a) is high. The EAS statement says that without specific Lp(a)-lowering therapies, the answer is early, intensive management of other risk factors, scaled to your overall cardiovascular risk. The NLA update recommends lifestyle changes and, for high-risk people, lipid-lowering drugs aimed mainly at LDL cholesterol, plus testing first-degree relatives. EAS adds that statins may raise Lp(a) slightly but the cardiovascular benefit in people with high Lp(a) far outweighs it. In practice, that means LDL cholesterol (or ApoB, if you have it measured), blood pressure, glucose and smoking, with a clinician who has seen the number. Our guide to high ApoB with a normal LDL covers the particle-count marker, and the lipid panel guide covers what a standard panel leaves out. If you have never been tested, Lp(a) usually has to be requested by name. Two of the expert panels in our longevity hub list it.

What about the drugs. The first outcomes trial of an Lp(a)-lowering drug, pelacarsen, lowered Lp(a) and did not meet its primary endpoint in Novartis’s September 2026 topline release (company-reported, full data pending). We cover that result and what it means for testing in a separate post. It leaves the lifespan question open. Whether lowering Lp(a) returns the one to two years seen in the top 5% is unknown, and none of the studies above tested it.